The burden of CKD resulting from T2D, quantified with disability and mortality risk measures, has increased since 1990, mostly due to population expansion and ageing [2]
Batth, T
However, with the advent of incretin treatment, there are now pharmacological options that result in weight loss of 15 to 20% bodyweight, which approaches that achieved with bariatric surgery, and substantial cardiovascular benefit
Still, Skovronsky said, "I think we're making history here, both on the high end with the high dose and on the low dose for what we can offer patients." "For some patients, 30% weight loss may be more than what they're seeking," Skovronsky later added
The bigger factor is supply chain proximity
Theres currently no generic alternative available for Ozempic